Emcure Pharmaceuticals � IPO Note: Dolat Capital

[email protected]02 Nov, 2021News

Emcure Pharmaceuticals Ltd. has a diversified revenue profile, with 44% revenue from India, 31% from U.S./Canada, and 12% from Europe. Apart from an established market position (ranked 12th) in IPM, Emcure has increased its presence in Europe and Canada by establishing front-end marketing network through acquisitions of Tillomed Laboratories (U.K.), Marcan Pharmaceuticals (Canada).